Lucius LuciPazo pazopanib 200mg

Product Information

• Product name: LuciPazo pazopanib 200mg
• Manufacturer / brand: Laos Lucius Pharma
• Active ingredient: Pazopanib
• Current strength: 200mg
• SKU: LU-ITEM-149
• Site category: kidney cancer, soft tissue sarcoma, other cancer

Product Summary

LuciPazo pazopanib 200mg is an AISTIKA-listed product supplied by Laos Lucius Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Pazopanib is the active ingredient used for this product page. Public prescribing information for Pazopanib was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-ɑ and -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kinase (Itk), lymphocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c­-Fms).

Reference Indications

Pazopanib tablets are a kinase inhibitor indicated for the treatment of adults with: advanced renal cell carcinoma (RCC). advanced soft tissue sarcoma (STS) who have received prior chemotherapy. Limitations of Use: The efficacy of Pazopanib tablets for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated. Limitations of Use : The efficacy of Pazopanib tablets for the treatment of patients with adipocytic STS or gastrointestinal stromal tumors has not been demonstrated.

Reference Dosage and Administration

Recommended Dosage: 800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal). Swallow tablets whole.

With this 200mg product, that corresponds to 4 x 200mg tablets when that reference dose is clinically appropriate.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

WARNING: HEPATOTOXICITY Severe and fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended . WARNING: HEPATOTOXICITY See for complete boxed warning. Severe and fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended. Hepatic Toxicity: Severe and fatal hepatotoxicity has occurred. Monitor liver tests at baseline, regularly during treatment and as clinically indicated. Withhold Pazopanib tablets and resume at reduced dose with continued weekly monitoring for 8 weeks, or permanently discontinue with weekly monitoring until resolution based on severity of hepatotoxicity.

Common Adverse Reactions and Monitoring

The data described in the section reflect exposure of 977 patients who received Pazopanib tablets as a single agent, including 586 Pazopanib-treated patients with RCC. The data described in the also reflects exposure of 382 patients with advanced soft tissue sarcoma who received Pazopanib tablets as a single agent, with a median duration of treatment of 3.6 months (range, 0 to 53). Renal Cell Carcinoma The safety of Pazopanib tablets was evaluated in 290 patients with RCC who participated in VEG105192, a randomized, double-blind, placebo-controlled trial . The median duration of treatment was 4.5 months (range, 0 to 24) for patients who received Pazopanib tablets.

Drug Interactions and Special Populations

Strong CYP3A4 Inhibitors: Avoid coadministration of Pazopanib tablets with strong CYP3A4 inhibitors. If coadministration cannot be avoided, reduce the dose of Pazopanib tablets. ( 2.4 , 7.1 ) Strong CYP3A4 Inducers: Consider an alternate concomitant medication with no or minimal enzyme induction potential. Pazopanib tablets are not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. ( 2.4 , 7.1 ) CYP Substrates: Coadministration of Pazopanib tablets with agents with narrow therapeutic windows that are metabolized by CYP3A4, CYP2D6, or CYP2C8 is not recommended. Concomitant Use With Simvastatin: Concomitant use of Pazopanib tablets with simvastatin increases the risk of alanine aminotransferase (ALT) elevations. Increase to weekly monitoring of liver function as recommended.

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: Pazopanib public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.